We have 2 exciting postdoc openings in our Medicinal Chemistry Drug Design department @merckgroup: for our collaboration with @LabThoma @EPFL_en (molecular glue degrader identification); for @proxidrugs w/ @Hausch_lab & Stefan Knapp (novel E3 for #PROTACs) https://t.co/4iQtL8T8J0

The University of Bonn offers two PhD scholarship financed by the DAAD within the DAAD-GSSP Programme. The PhD students will be associated to the Research Training Group RTG/GRK 2873 @grk2873. Apply now! Please RT.

We are #hiring! We have an open #postdoctoral position in my group with the focus on structural biology #cryoEM and X-ray crystallography of new #E3 ligases as well as #molecularglue complexes. @UniBonn @IsbBonn https://t.co/SYxOT8RwCi Please RT!

Excited about #TPD and #InducedProximity? So are we, and we are recruiting! #postdoc #technician #NowakLab #Germany @UniBonn @UniklinikBonn @ImmunoSens Please DM or reach us on

Welcome to Bonn, and all the best for your start!!! I am looking forward to exploring CIP modalities with you 👨‍🔬💊

Highly interdisciplinary study. Thanks to everyone involved! @HartmannLab @KroenkeLab @FKH_Lab @IzidorSosic @grk2873

🚀 New Study Alert! Our benzamide-type CRBN binders redefine PROTAC design. The non-phthalimide scaffold led to: ✅ Enhanced chemical stability ✅ Minimized neomorphic effects ✅ Potent BRD4 & HDAC6 degraders 🌐 Read our full study: https://t.co/MlHM8ugTEg #MedChem #PROTACs

My lab is interested in USP7 as well and published, along with a competitor‘s lab, USP7 PROTACs before. Why both manuscripts are not cited? Furthermore, the authors claim to have synthesized 66 (!) PROTACs, but only 1 structure is shared. Disappointed about the reviewer‘s work…

Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1 | Cell Death & Differentiation (PROTACs included #TPD )

Multi-Target Degradation #TPD (targeted pasta degradation) with @IzidorSosic and excellent finish of the #BioMedConference @IRBBarcelona

2nd evening in Barcelona #BarcelonaBioMed @IRBBarcelona conference hosted by @CrisMayorRuiz and @georg_e_winter with the #TPD crew @IzidorSosic @FKH_Lab @RPNowak @MaxSticks7 enjoying dinner near seaside

Well, the blue colored compound was a Cy5 dye. 😃 (some months ago we also made a bodipy derivative, but it was not really compatible with the ligand properties…)

Let’s see if #chemtwitter can guess the dye…

It’s #FluorescenceFriday so some #RealTimeChem from my lab: purification (until battery crashed) of a fluorescently labelled non-chiral, non-glutarimide/uracile CRBN ligand with outstanding affinity. #TPD tweeps, it will blow your mind 🤯 next step: in vitro assays @HartmannLab

May I enter the #chemistswhocook club? @ChemEpi Beef filet sous vide, potato fries, tomato salad. A present to my strong wife who gave birth of our son Jan 21.04.23 ❤️ #daddy

Great interdisciplinary work from @IzidorSosic @FKH_Lab @KroenkeLab @HartmannLab and many more!

4/4 further property assessment, including physicochemical properties, stability and neosubstrate features refined our ligand selection. Derived PROTACs for BRD4 and HDAC6 were potent, stable, and with little neomorphic activity (as ARV-776 is). Thx @kdonovan1008 for proteomics!

3/4 we synthesized benzamides with 6 different substituents in the ortho position and amino exit vector in the para position. 💎Crystal structures could be solved for all compounds. IMHB determined ligand conformation. NMR studies suggest that the IMHBs do also exist in solution

2/4 fluorinated thal derivatives were in our research focus since years (Gütschow 2001, Ambrożak 2016). In 2021 (CRBN age) we published encouraging binding data of tetrafluorinated benzamides. We now know, that the type and position of the substituent is important due to IMHBs

📢New preprint: multidimensional design of benzamide CRBN binders & #PROTACs - #TPD tweeps will surely enjoy the MedChem journey: binding data, X-ray structures, reactivity screens, neosubstrate-sparing degraders, cool synthetic methods. 1/4 👉 ChemRxiv